a. Hydroxychloroquine Sulphate and Chloroquine Phosphate APIs produced at the Company's APls manufacturing unit situated at Ratlam (Madhya Pradesh); and

b. Hydroxychloroquine Sulphate Tablets produced at the Company's formulations manufacturing units situated at SEZ Indore, Pithampur (Madhya Pradesh) and Piparia (Silvassa).

US FDA has also informed that their exception will be re-considered if the shortage implications change.

The company further announced that foreseeing the increased demand, it is gearing to manufacture and supply these products.